Lightcalls.com
 

Vitamin C remodels levels of a mar...

Vitamin C remodels levels of a marker for inflammation--a protein that has been more earnestly linked to heart disease than cholesterol levels

A University of California, Berkeley, contemplation reported in the April 2004 issue of the Journal of the American corporation of Nutrition shows that daily doses of 500 milligrams (mg) of vitamin C lower C-reactive protein (CRP) plains by 24 percent after 2 months

The vitamin C must be taken by the agency of itself. Patients receiving an antioxidant containing vitamins C and E and alpha-lipoic acid experienced no significant CRP reduction. No individual knows why, but it's possible that an interaction among the antioxidants giveed the mixture less effective.

High CRP readings indicate inflammation, which is increasingly blamed for heart disease in a certain quantity of people who have healthy evens of cholesterol and triglycerides. In fact, a large number of heart attack victims previously exampleed low for cholesterol.

CRP is also linked to diabetes and Alzheimer's disease risk.



Inflammation befalls as part of the body's defense against infection or injury. The carcass triggers the production of inflammatory cytokines, similar as interleukin-6, which then trigger the production of CRP by means of the liver. How vitamin C intersects CRP levels is unclear, yet the vitamin might block production of these cytokines.

Inflammation flats can go to 100-fold with an infection, although they least bit after the infection cures.

Elevated CRP concentration have been institute in obese people, indicating that obesity is associated with inflammation. This may help explain for what cause [i]or[/i] reason overweight people are at an increased risk for diabetes, heart disease and certain adumbrations of cancer.

If the subject of attention results can be duplicated and the National Institutes of Health has awarded a grant for another trial of vitamin C to confirm the findings--vitamin C fill ups may become an inexpensive intervention for heart disease.

COPYRIGHT 2004 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2004 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.